Form 4: Arteris CEO Sells 50,000 Shares Under 10b5-1 Plan

Arteris, Inc. President and CEO, K. Charles Janac, sold 50,000 shares of common stock on January 8, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• K. Charles Janac, President and CEO, Director, and 10% Owner of Arteris, Inc. (AIP), reported a sale of 50,000 shares of common stock.
• The transaction occurred on January 8, 2026.
• The shares were sold at a weighted average price of $16.5831, with individual sales ranging from $16.2150 to $17.3600.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Janac on March 5, 2025.
• Following the transaction, Mr. Janac directly beneficially owns 139,487 shares of common stock.
• Additionally, Mr. Janac indirectly beneficially owns 9,419,071 shares through Bayview Legacy, LLC, where he is the manager, and 56,252 shares through the Charles and Lydia Janac Trust, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sale of shares by a key executive is generally viewed neutrally to slightly negatively. However, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sale is based on new, negative non-public information, making it an expected, planned liquidity event.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, adopted on March 5, 2025, which indicates a planned liquidity event rather than a reaction to recent non-public information.

Negatives

• An insider sale by a key executive (President and CEO, Director, and 10% Owner) could be interpreted by some investors as a lack of confidence, despite the 10b5-1 plan.
• The sale represents a reduction in direct beneficial ownership by 50,000 shares.

Risks

• No specific risks are mentioned in the Form 4 filing itself, beyond the potential market interpretation of an insider sale.

Future Outlook

NA

Management Comments

• The transaction was made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 5, 2025.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

This filing is specific to an individual insider transaction at Arteris, Inc. and does not provide broader industry context or trends. Insider transactions are a routine part of the market, and 10b5-1 plans are common for executives to manage personal finances while complying with insider trading rules.

Related Party Transactions

• The reporting person indirectly beneficially owns shares through Bayview Legacy, LLC, where he is the manager.
• The reporting person indirectly beneficially owns shares through the Charles and Lydia Janac Trust, for which he serves as trustee.

Stakeholder Impact

• Shareholders may interpret the insider sale, even under a 10b5-1 plan, as a signal regarding management's long-term view of the company, potentially influencing investor sentiment.

Key Dates

Recommendation

While an insider sale by a CEO can sometimes be a negative signal, this transaction was conducted under a pre-established 10b5-1 trading plan. Such plans are designed to allow insiders to sell shares for personal financial planning purposes without being accused of trading on material non-public information. Therefore, this specific sale is likely a planned liquidity event and does not necessarily indicate a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

Arteris Inc., AIP, Form 4, insider trading, stock sale, 10b5-1 plan, K. Charles Janac, CEO, director, beneficial ownership, equity transaction